Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22584713 | 0.82 | CHRM4 (0.50) | CHRM4FAAHMCHR1KCNH2SSTR5 | |
| SCHEMBL22606972 | 0.80 | SSTR5 (0.51) | CHRM4FAAHMCHR1SSTR5MAPT | |
| SCHEMBL22606800 | 0.78 | CHRM4 (0.55) | CHRM4FAAHMCHR1KCNH2MCHR2 | |
| SCHEMBL22606683 | 0.76 | CHRM4 (0.56) | CHRM4FAAHMCHR1MAPTALDH1A1 | |
| SCHEMBL22606652 | 0.76 | ACKR3 (0.57) | CHRM4FAAHMCHR1MAPT | |
| SCHEMBL22606629 | 0.76 | CHRM4 (0.49) | CHRM4FAAHMCHR1KCNH2MCHR2 | |
| SCHEMBL22606649 | 0.76 | CHRM4 (0.51) | CHRM4FAAHMCHR1KCNH2MCHR2 | |
| SCHEMBL22607012 | 0.75 | CHRM4 (0.50) | CHRM4FAAHMCHR1KCNH2MCHR2 | |
| SCHEMBL22606644 | 0.75 | LMNA (0.56) | CHRM4FAAHLMNAMAPTALDH1A1 | |
| SCHEMBL22584711 | 0.74 | LTA4H (0.63) | CHRM4FAAHMCHR1KCNH2MCHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | ENHANCEDBIO, INC. (KR) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339537-A1 | NOVEL COMPOUND AS INHIBITOR AGAINST BINDING OF PF34 PROTEIN TO NEDD4-1 PROTEIN AND USE THEREOF | NEDD4, PFDN1, PF4 | CHRM4 3387/4885FAAH 4096/4885MCHR1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.